FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2020173286> ?p ?o ?g. }

• W2020173286 endingPage "A72" @default.
• W2020173286 startingPage "A72" @default.
• W2020173286 abstract "Abstract Background: Gal-1 is a lectin with multiple biological functions including tumor progression, migration, and angiogenesis. OTX008, a small molecule downregulating gal-1 protein level, displays direct antiproliferative and anti-invasive effects in human cancer cells. Objectives: Determine the maximum tolerated dose (MTD) of single agent OTX008 using a subcutaneous (SC) daily dosing based on dose-limiting toxicities (DLTs). Secondary objectives were safety, pharmacokinetics (PK), pharmacodynamics (PD), and antitumor activity. Patients and Methods: Patients (pts) with solid tumors having failed standard therapies, and given a written consent were enrolled. OTX008 was delivered as daily SC injection. In case of DLT, treatment was interrupted until recovery and resumed at the dose level (DL) below. Dose was escalated according to a 3+3 design. The MTD was defined as the highest DL, in which ≤1/6 pt experiences a DLT. Results: 22 pts (50% with colorectal carcinoma) were treated from March 2012 to March 2013. Six were enrolled at DL1 (65mg-flat dose) without DLT. Among the 7 pts enrolled at DL2 (120-130mg), 2 experienced DLT. DL2 was therefore deemed to exceed the MTD and 9 additional pts were enrolled at DL1. No DLT was observed among the 15 patients treated at DL1. The most frequent related adverse event (AE) was G1-2 injection site reaction in 20 patients. Two pts experienced skin ulcerations, resulting in subcutaneous abscess and treatment discontinuation in one and consent withdrawal in another. Transient and fully reversible neurological AEs were observed in 12 pts (55%), and were more frequent (100% vs 33%) and more severe (G3 in 29% vs 0%) at DL2 compared to DL1 respectively. G 1-2 tremor was observed in 8 pts, perioral paresthesia in 5, dizziness in 4 and myoclonia in 2. Two patients experienced G3 ataxia (DLT), and one patient with past history of post-traumatic epilepsy experienced G3 seizure. Gastrointestinal (GI) AEs were reported by 12 pts (55%); G3 vomiting/abdominal pain and G3 diarrhea were reported in 1 pt each; 12 patients developed asymptomatic abnormal lab values (10 hypomagnesemia and 8 transient elevation of CPK without rhabdomyolysis or cardiac ischemia). OTX008 plasma concentrations were &gt;1µM over 12h after administration. PK of OTX008 is best described by a two compartment open model and showed less than proportional exposure increase, possibly due to wide inter-patient variability. The main covariate effect was related to body weight. Plasma gal-1 levels decreased proportionally with increasing OTX008 plasma concentrations. Serial tumor biopsies in 6 patients did not conclude on a PD effect. No objective response was reported. Conclusions: OTX008 recommended flat daily sc dose is 65mg, which achieves significant systemic plasma concentrations based on in vitro models. Weight adapted dosing may optimize systemic exposure. Local tolerance of SC injection is poor.Reversible ataxia was a dose-limiting toxicity. Citation Information: Mol Cancer Ther 2013;12(11 Suppl):A72. Citation Format: Jean-Pierre Delord, Ahmad Awada, Eric Raymond, François Lokiec, Patrice Herait, Keyvan Rezai, Nicolas Lachaux, Gabriel A. Rabinovich, Carlos Gomez-Roca, Philippe Aftimos, Sandrine Faivre, Juan Carlos Stupirski. A first-in-man Phase I study of the galectin-1 (gal-1) inhibitor OTX008 given subcutaneously as a single agent to patients with advanced solid tumors. [abstract]. In: Proceedings of the AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics; 2013 Oct 19-23; Boston, MA. Philadelphia (PA): AACR; Mol Cancer Ther 2013;12(11 Suppl):Abstract nr A72." @default.
• W2020173286 created "2016-06-24" @default.
• W2020173286 creator A5002046745 @default.
• W2020173286 creator A5002864173 @default.
• W2020173286 creator A5006004932 @default.
• W2020173286 creator A5006910154 @default.
• W2020173286 creator A5010064853 @default.
• W2020173286 creator A5013952219 @default.
• W2020173286 creator A5024226262 @default.
• W2020173286 creator A5028020706 @default.
• W2020173286 creator A5032111284 @default.
• W2020173286 creator A5043993292 @default.
• W2020173286 creator A5050540160 @default.
• W2020173286 creator A5078388793 @default.
• W2020173286 date "2013-11-01" @default.
• W2020173286 modified "2023-10-17" @default.
• W2020173286 title "Abstract A72: A first-in-man Phase I study of the galectin-1 (gal-1) inhibitor OTX008 given subcutaneously as a single agent to patients with advanced solid tumors." @default.
• W2020173286 doi "https://doi.org/10.1158/1535-7163.targ-13-a72" @default.
• W2020173286 hasPublicationYear "2013" @default.
• W2020173286 type Work @default.
• W2020173286 sameAs 2020173286 @default.
• W2020173286 citedByCount "10" @default.
• W2020173286 countsByYear W20201732862019 @default.
• W2020173286 countsByYear W20201732862020 @default.
• W2020173286 countsByYear W20201732862021 @default.
• W2020173286 countsByYear W20201732862022 @default.
• W2020173286 countsByYear W20201732862023 @default.
• W2020173286 crossrefType "journal-article" @default.
• W2020173286 hasAuthorship W2020173286A5002046745 @default.
• W2020173286 hasAuthorship W2020173286A5002864173 @default.
• W2020173286 hasAuthorship W2020173286A5006004932 @default.
• W2020173286 hasAuthorship W2020173286A5006910154 @default.
• W2020173286 hasAuthorship W2020173286A5010064853 @default.
• W2020173286 hasAuthorship W2020173286A5013952219 @default.
• W2020173286 hasAuthorship W2020173286A5024226262 @default.
• W2020173286 hasAuthorship W2020173286A5028020706 @default.
• W2020173286 hasAuthorship W2020173286A5032111284 @default.
• W2020173286 hasAuthorship W2020173286A5043993292 @default.
• W2020173286 hasAuthorship W2020173286A5050540160 @default.
• W2020173286 hasAuthorship W2020173286A5078388793 @default.
• W2020173286 hasConcept C111113717 @default.
• W2020173286 hasConcept C112705442 @default.
• W2020173286 hasConcept C121608353 @default.
• W2020173286 hasConcept C126322002 @default.
• W2020173286 hasConcept C143998085 @default.
• W2020173286 hasConcept C197934379 @default.
• W2020173286 hasConcept C2777288759 @default.
• W2020173286 hasConcept C2778715236 @default.
• W2020173286 hasConcept C71924100 @default.
• W2020173286 hasConcept C90924648 @default.
• W2020173286 hasConcept C98274493 @default.
• W2020173286 hasConceptScore W2020173286C111113717 @default.
• W2020173286 hasConceptScore W2020173286C112705442 @default.
• W2020173286 hasConceptScore W2020173286C121608353 @default.
• W2020173286 hasConceptScore W2020173286C126322002 @default.
• W2020173286 hasConceptScore W2020173286C143998085 @default.
• W2020173286 hasConceptScore W2020173286C197934379 @default.
• W2020173286 hasConceptScore W2020173286C2777288759 @default.
• W2020173286 hasConceptScore W2020173286C2778715236 @default.
• W2020173286 hasConceptScore W2020173286C71924100 @default.
• W2020173286 hasConceptScore W2020173286C90924648 @default.
• W2020173286 hasConceptScore W2020173286C98274493 @default.
• W2020173286 hasIssue "11_Supplement" @default.
• W2020173286 hasLocation W20201732861 @default.
• W2020173286 hasOpenAccess W2020173286 @default.
• W2020173286 hasPrimaryLocation W20201732861 @default.
• W2020173286 hasRelatedWork W2004325424 @default.
• W2020173286 hasRelatedWork W2021319218 @default.
• W2020173286 hasRelatedWork W2227061539 @default.
• W2020173286 hasRelatedWork W2245370565 @default.
• W2020173286 hasRelatedWork W2400384365 @default.
• W2020173286 hasRelatedWork W2403251648 @default.
• W2020173286 hasRelatedWork W2594910449 @default.
• W2020173286 hasRelatedWork W2992709639 @default.
• W2020173286 hasRelatedWork W3021369409 @default.
• W2020173286 hasRelatedWork W3174177415 @default.
• W2020173286 hasVolume "12" @default.
• W2020173286 isParatext "false" @default.
• W2020173286 isRetracted "false" @default.
• W2020173286 magId "2020173286" @default.
• W2020173286 workType "article" @default.